Arcutis Biotherapeutics Inc (NAS:ARQT)

Q2 2026 Arcutis Biotherapeutics Inc Earnings Call Transcript

Aug 5, 2026 / 08:30 PM GMT

Release Date Price: $27.1 (+4.11%)

Transcript 10-Q8-K

Key Points

Positve

Arcutis Biotherapeutics Inc (ARQT) reported strong Q2 2026 net product revenues of $129.9 million, a 59% increase year-over-year and a 23% sequential increase, driven by robust patient demand.
The company raised its full-year 2026 sales guidance to $525-$540 million, reflecting strong momentum and confidence in continued growth.
Received FDA approval for Zoryve Cream 0.3% in plaque psoriasis for children as young as 2, addressing a significant treatment gap and expanding the addressable patient population.
FDA accepted the supplemental NDA for Zoryve Cream 0.05% in atopic dermatitis for infants down to 3 months, with a PDUFA date in February 2027, potentially opening a large new market.
The company achieved positive net income of $15 million and positive operating cash flow of $12.6 million, demonstrating financial strength and sustainability.
Launched a virtual health platform and AI-enabled prescription workflow partnership to improve patient access and streamline the prescription process, which could drive additional growth.
Completed enrollment in the Phase 2 vitiligo trial and continues to advance the pipeline, including ARQ-234, a novel biologic for atopic dermatitis.
Expanded commercial infrastructure with a completed dermatology sales force expansion and a new primary care/pediatric sales team, expected to drive growth in 2027.
Zoryve maintains a leading market share of nearly 50% in the branded non-steroidal topical class, with strong prescription growth across all indications.
The company has a strong patent portfolio with 28 Orange Book-listed patents, providing long-term protection for its products.

Negative

Gross-to-net rates remain in the 50s, with only modest improvements expected in the second half of the year, limiting potential margin expansion.
The company anticipates that the primary care and pediatric sales force will not contribute meaningfully to growth until 2027, delaying potential upside.
The resignation of Chief Commercial Officer Todd Edwards introduces leadership transition risk, despite the appointment of an experienced interim CCO.
The company faces intense competition in the atopic dermatitis and vitiligo markets, with established players like Opzelura setting high benchmarks.
The Phase 2 vitiligo trial results are not expected until Q4 2026, and the HS trial readout is not until Q1 2027, creating uncertainty about pipeline expansion.
The company's reliance on external innovation and deal flow for pipeline growth may not materialize as expected, given the competitive landscape.
The virtual health platform is still in early stages, and its impact on sales is uncertain, with no clear conversion metrics yet.
The company's SG&A expenses increased 19% year-over-year due to sales force expansion, which could pressure profitability if revenue growth slows.
The potential approval for the infant indication is not until February 2027, leaving a gap before this market opportunity can be captured.
The company's guidance raise may not be sustainable if demand growth moderates, and management has indicated they do not plan to update guidance quarterly, which could lead to disappointment.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ARQT.OQ - Arcutis Biotherapeutics, Inc.
Q2 2026 Arcutis Biotherapeutics Inc Earnings Call
Aug 05, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for standing by. Welcome to our QDIS Biotherapeutics Inc. Second Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. And to ask a question during this session, you would need to press *11 on your telephone. You will then hear an automated message advising your hand is raised. And to withdraw your question, please press *11. Again.

Please be advised that today's conference is being recorded.

I would like now to turn the conference over to Brian Sholkoff, Head of Investor Relations. Please go ahead.

-----------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.